[{"id":"c39317e9-2ffe-4fe5-b487-781ec7511b8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923180","created_at":"2021-01-18T14:21:11.868Z","updated_at":"2024-07-02T16:34:25.763Z","phase":"Phase 2","brief_title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","source_id_and_acronym":"NCT02923180","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression","tags":["AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"},{"id":"8d7085c4-b70c-4d81-8155-40e3a80cc9f5","acronym":"HEAT","url":"https://clinicaltrials.gov/study/NCT06014255","created_at":"2023-08-28T14:08:37.514Z","updated_at":"2024-07-02T16:34:27.119Z","phase":"Phase 2","brief_title":"Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06014255 - HEAT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-1 • LAG3 • CD276 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" PD-L1 expression • LAMP1 expression","tags":["PD-1 • LAG3 • CD276 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-11"},{"id":"4bbdcbf6-ccbf-4476-adeb-a48a0a44206f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225363","created_at":"2022-02-05T18:29:53.670Z","updated_at":"2024-07-02T16:35:01.290Z","phase":"Phase 1","brief_title":"Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05225363","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAG72-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2027","study_completion_date":" 04/05/2027","last_update_posted":"2024-05-23"},{"id":"d5819f8b-eef3-4921-8ec5-7ad92269151b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05634707","created_at":"2022-12-02T16:57:11.446Z","updated_at":"2024-07-02T16:35:18.987Z","phase":"Phase 1","brief_title":"Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)","source_id_and_acronym":"NCT05634707","lead_sponsor":"Duke University","biomarkers":" LAMP1","pipe":" | ","alterations":" LAMP1 expression • IDH wild-type","tags":["LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAMP1 expression • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • fluoxetine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/05/2023","start_date":" 08/05/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-19"},{"id":"590e53d1-c310-49ee-97e0-d23db9389e60","acronym":"16-C-0048","url":"https://clinicaltrials.gov/study/NCT02649855","created_at":"2023-07-21T15:09:43.248Z","updated_at":"2024-07-02T16:35:31.054Z","phase":"Phase 2","brief_title":"Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer","source_id_and_acronym":"NCT02649855 - 16-C-0048","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • MUC1 • TNFA • CEACAM5 • CD4 • IL2 • LAMP1","pipe":"","alterations":" ","tags":["CD8 • IFNG • MUC1 • TNFA • CEACAM5 • CD4 • IL2 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • ProstVac (rilimogene galvacirepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/19/2016","start_date":" 01/19/2016","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 08/08/2024","study_completion_date":" 08/08/2024","last_update_posted":"2023-10-31"},{"id":"9ae4eede-f757-4258-926b-cb6caf976257","acronym":"","url":"https://clinicaltrials.gov/study/NCT05967533","created_at":"2023-08-01T16:10:23.357Z","updated_at":"2024-07-02T16:35:41.462Z","phase":"Phase 1","brief_title":"The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors","source_id_and_acronym":"NCT05967533","lead_sponsor":"University of California, Davis","biomarkers":" CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20","pipe":" | ","alterations":" IFNG expression","tags":["CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 06/02/2025","primary_completion_date":" 06/02/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-01"},{"id":"a1a28924-3b81-4b2a-820f-63500e9cd986","acronym":"","url":"https://clinicaltrials.gov/study/NCT05038722","created_at":"2021-09-09T13:53:04.591Z","updated_at":"2024-07-02T16:35:43.153Z","phase":"","brief_title":"Function of Platelets Used for Transfusions","source_id_and_acronym":"NCT05038722","lead_sponsor":"Sofia Ramström","biomarkers":" LAMP1","pipe":"","alterations":" ","tags":["LAMP1"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 240","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-07-13"},{"id":"e3f3d87c-042b-41d5-85e7-f64a91c593c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922921","created_at":"2021-01-18T08:40:49.420Z","updated_at":"2025-02-25T14:00:14.999Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy","source_id_and_acronym":"NCT01922921","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG • NCAM1 • LAMP1","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • IFNG • NCAM1 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp) • AST-301"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/05/2014","start_date":" 02/05/2014","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2023-04-18"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"cca55acd-fe7d-4fd1-a867-4d67afcb638c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02179515","created_at":"2021-01-18T10:09:59.893Z","updated_at":"2024-07-02T16:36:35.567Z","phase":"Phase 1","brief_title":"Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)","source_id_and_acronym":"NCT02179515","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4","pipe":" | ","alterations":" ER positive • EGFR mutation • CD8 expression","tags":["CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR mutation • CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BN-Brachyury"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 06/28/2014","start_date":" 06/28/2014","primary_txt":" Primary completion: 04/06/2017","primary_completion_date":" 04/06/2017","study_txt":" Completion: 02/28/2018","study_completion_date":" 02/28/2018","last_update_posted":"2021-01-26"},{"id":"0026d81a-cc97-48d8-bf24-2665e6d416d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03665571","created_at":"2021-05-03T11:02:25.289Z","updated_at":"2024-07-02T16:37:07.023Z","phase":"","brief_title":"Evaluation of Killing Activity of Expanded Natural Killer Cells From Blood in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT03665571","lead_sponsor":"Asan Medical Center","biomarkers":" IFNG • LAMP1","pipe":" | ","alterations":" LAMP1 expression","tags":["IFNG • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAMP1 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2018-09-11"},{"id":"83c22f29-8ff8-4888-9f27-319e4ca38fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01519817","created_at":"2021-01-18T06:23:30.321Z","updated_at":"2024-07-02T16:37:14.401Z","phase":"Phase 1","brief_title":"Cancer Vaccine Targeting Brachyury Protein in Tumors","source_id_and_acronym":"NCT01519817","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • TNFA • CD4 • IL2 • CD27 • LAMP1 • CD40LG","pipe":" | ","alterations":" ER positive • CD8 expression","tags":["CD8 • TNFA • CD4 • IL2 • CD27 • LAMP1 • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GI-6301"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/05/2012","start_date":" 01/05/2012","primary_txt":" Primary completion: 03/03/2016","primary_completion_date":" 03/03/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2018-01-29"},{"id":"ec2197c4-0016-4dba-b7ff-d215f60c5c5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01727076","created_at":"2021-01-18T07:32:38.065Z","updated_at":"2024-07-02T16:37:17.894Z","phase":"Phase 1","brief_title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","source_id_and_acronym":"NCT01727076","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTLA4 • LAMP1 • IL15","pipe":"","alterations":" ","tags":["CTLA4 • LAMP1 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/15/2013","start_date":" 02/15/2013","primary_txt":" Primary completion: 06/30/2016","primary_completion_date":" 06/30/2016","study_txt":" Completion: 06/30/2016","study_completion_date":" 06/30/2016","last_update_posted":"2017-09-15"},{"id":"9d7c0b8b-f94d-4f80-b0a0-98faeaae6298","acronym":"","url":"https://clinicaltrials.gov/study/NCT01852591","created_at":"2021-01-18T08:16:16.707Z","updated_at":"2024-07-02T16:37:26.032Z","phase":"","brief_title":"Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant","source_id_and_acronym":"NCT01852591","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IFNG • CD4 • LAMP1","pipe":"","alterations":" ","tags":["IFNG • CD4 • LAMP1"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2017-02-02"}]